key: cord-1008231-3guwd0ua
authors: Peravali, M.; Joshi, I.; Ahn, J.; Kim, C.
title: A Systematic Review and Meta-analysis of Clinical Characteristics and Outcomes in Lung Cancer Patients with COVID-19
date: 2021-01-07
journal: JTO Clin Res Rep
DOI: 10.1016/j.jtocrr.2020.100141
sha: db528f39aa3c7934765658c80a00299d008cf5ad
doc_id: 1008231
cord_uid: 3guwd0ua

Background Cancer is considered to be an independent risk factor for severe illness and higher mortality in patients with Coronavirus disease 2019 (COVID-19). These adverse outcomes have been suspected to be more severe in lung cancer patients. The objective of this systematic review and meta-analysis is to outline patient characteristics, challenges in diagnosis and treatment, and outcomes of lung cancer patients with COVID-19. Methods A comprehensive search was conducted using EMBASE and PUBMED databases using the terms “COVID” and “cancer.” Studies that reported clinical characteristics and/or outcomes of lung cancer patients with COVID-19 were then systematically identified. Meta-analysis for COVID-19 related mortality associated with lung cancer compared to other cancer types was conducted. The results were reported as odds ratio (OR) and confidence intervals (CI) using mixed-effects logistic regression model. Results The most commonly reported clinical findings in lung cancer patients with COVID-19 were fever and cough, with 68% and 61%, respectively. Laboratory and radiographic findings were consistent with broadly reported data. The meta-analysis noted a statistically significant increase in mortality rate in lung cancer patients compared to other cancer patients, OR 1.62 (95% CI: 1.06-2.48). Lung cancer patients with COVID-19 also reflected greater severity of illness and higher rates of ICU admissions and mechanical ventilation. Conclusions COVID-19 in lung cancer patients is associated with severe disease and increased mortality relative to patients with other malignancies and the general population. There is conflicting evidence on the effect of specific lung cancer treatments on outcomes. Until more definitive data is available, lung cancer directed treatment should be continued or restarted as early as possible in mild to moderate cases to prevent worsening cancer-related mortality.

population. There is conflicting evidence on the effect of specific lung cancer treatments on outcomes. Until more definitive data is available, lung cancer directed treatment should be continued or restarted as early as possible in mild to moderate cases to prevent worsening cancer-related mortality.

• Patients with lung cancer and COVID-19 infection have higher mortality rates compared to patients with other cancer types.

• Rates of severe illness, ICU admissions and mechanical ventilation are also higher in lung cancer patients.

• Clinical, laboratory and radiographic characteristics are similar to reports in the general population.

• There is conflicting data regarding the effect of specific lung cancer treatments on outcomes.

J o u r n a l P r e -p r o o f BACKGROUND Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was first identified in Wuhan, Hubei province, China in December 2019. 1 Since then, it has rapidly spread worldwide, with more than 27.3 million cases reported as of September 8, 2020. 2 The clinical characteristics of the illness are highly variable ranging from asymptomatic disease to mild, self-limiting cases to severe disease requiring ICU admission and mechanical ventilation. 3 Mortality rate is also highly variable and several disease specific markers and pre-existing medical comorbidities have been identified as risk factors for increased mortality in these patients. 3 Cancer is confirmed to be an independent risk factor for adverse events and mortality in patients with COVID-19. [4] [5] [6] [7] Other adverse events such as incidence of intubation and mechanical ventilation use are also higher in cancer patients. 5 The impact of COVID-19 infection on lung cancer patients was reported in several studies with increased mortality noted when compared to other cancer types. [6] [7] [8] [9] [10] [11] [12] [13] However, many of these studies were limited to small cohort of patients with single institution experience. Preliminary data from a large global multicenter observational study of patients with thoracic malignancy reported mortality rate to be as high as 33%. 14 The objective of this systematic review is to describe clinical characteristics, challenges in diagnosis, and outcomes of patients with lung cancer who were confirmed to have COVID-19 infection. A meta-analysis of COVID-19 related mortality in lung cancer patients compared to patients with other malignancies is included. We also describe the effects of different lung cancer directed treatments on outcomes.

J o u r n a l P r e -p r o o f METHODS This systematic review and meta-analysis was done in accordance with guidelines set forth by Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. 15 A comprehensive search was done using EMBASE and PUBMED databases using the words "COVID" and "cancer." In addition, American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR) 2020 annual meetings were manually searched for relevant abstracts. A manual search using other search engines such as Google Scholar and references of relevant articles was also conducted.

All case reports, retrospective and observational studies as well as prospective studies that reported clinical characteristics and/or outcomes of lung cancer patients who acquired COVID-19 infection were included in the study. Pre-clinical data including animal and cell line studies, reviews/meta-analyses, commentaries and guidelines were excluded.

Two reviewers (M.P. and I.J.) systematically surveyed titles and abstracts to identify relevant articles for full review. An independent review of the selected full-text articles was conducted using the above pre-specified selection criteria.

Discrepancies were resolved by consensus with a third reviewer (C.K.).

Pertinent clinical data extracted from the selected studies included patient symptoms, laboratory and radiographic features, and type of cancer-directed therapy received prior to infection. Outcomes data including severity of illness, rates of intubation and ICU admissions, and mortality were also extracted.

Selected studies that contained mortality data of lung cancer patients in comparison to other cancer types were included in the meta-analysis. The remaining relevant data was synthesized descriptively for the review.

The number of COVID-19 patients and deaths in lung cancer or other cancer of each study were used to evaluate COVID-19 related mortality associated with lung cancer. The odds ratio (OR) was calculated for each study where a continuity correction by adding 0.5 was applied when a study contains zero events. Mixed-effects logistic regression model with random study effects were fitted. Confidence intervals (CI) for the OR were calculated using a tdistribution. 16 Study specific heterogeneity was assessed using the l 2 statistic (0% to 100%) where a lower value implies less heterogeneity. The between-study variance tau 2 was computed using the maximum likelihood method and tested for the assumption of homogeneity using the Wald test. Funnel plot asymmetry was evaluated using Egger's linear regression test. 17 A two-sided p value of less than 0.05 for OR was determined to be statistically significant. All statistical analysis was carried out using meta library in R software version 3.4.

A total of 1819 articles were identified following an initial comprehensive search using large databases, national meetings and manual search. 106 full articles were selected for further review out of which 36 studies were chosen for qualitative synthesis for the review. 12 studies included mortality data for both lung cancer patients and other cancer patients and thus were eligible for the meta-analysis (Figure 1 al. 20 , a patient with small-cell lung cancer was treated with concurrent chemotherapy and radiation following which she developed new onset cough and dyspnea within the window of radiation pneumonitis 9 weeks later. However, after testing positive for COVID-19, she was successfully managed without the use of steroids. Guerini et al. 24 described a patient with lung adenocarcinoma treated with durvalumab whose atypical immune-related pneumonitis was successfully treated with steroids, following which he developed worsening respiratory symptoms, subsequently tested positive for COVID-19 and died of respiratory failure.

The symptoms of COVID-19 can also overlap with usual postoperative clinical course, resulting in delay in diagnosis. 25 In cases of thoracic surgery, fever and cough from reactive pleural effusion and atelectasis are common post-operative symptoms. Dyspnea secondary to lung resection and chest tightness, fatigue, loss of appetite, and nausea due to postoperative analgesics is also widely observed. 26 In a retrospective study of eleven patients with COVID-19 after thoracic surgery conducted by Peng et al. 8 , case fatality was significantly associated with degree of surgical resection defined by more than five resected lung segments. Additionally, lung cancer patients with COVID-19 after thoracic injury were found to have a greater incidence of severe illness. 8

Computed tomography (CT) of the chest is an important diagnostic modality for COVID-19 infection. Studies conducted on cancer patients with COVID-19 have observed bilateral lung involvement and peripheral distribution with common radiologic patterns including ground-glass opacities, smooth or irregular interlobular septal thickening, crazy-paving pattern, and thickening of adjacent pleura. 27 Imaging findings of COVID-19 infection in patients with lung cancer J o u r n a l P r e -p r o o f include multiple patchy ground-glass opacities and consolidations. 28, 29 Garassino et al. 14 reported 6.5% (n=13/200) of their patient cohort had radiological findings that were highly suggestive of COVID-19 and ultimately led to diagnosis despite negative RT-PCR test. In a cohort of radiation oncology patients, an asymptomatic lung cancer patient tested positive following identification of new bilateral ground-glass opacities on a CT scan obtained prior to delivery of first fraction for definitive stereotactic ablative radiotherapy (SABR). 30 Another study conducted by Peng et al. 8 Alternative imaging techniques are also valuable. Suppli et al. 21 reported a case in which cone bean computed tomography (CBCT) images, collected as a part of daily radiotherapy imaging, displayed patchy consolidation in the sub-pleural region and middle lobe in a patient with pulmonary adenocarcinoma. There was noticeable progression in the following treatment fractions, and ground glass opacities were visible on CBCT images 36 hours before the patient began to exhibit clinical symptoms of COVID-19. Therefore, these images, which are routinely collected in conjunction with the patient's treatment, can provide early signs supporting COVID-19 testing and should be carefully examined for radiologic abnormalities. Several studies have also reported the appearance of COVID-19 in x-rays. Patchy or diffuse interstitial reticulonodular opacities and consolidations with progressive bilateral lung changes are all potential signs of COVID-19 in patients with lung cancer. 21 Observing the progression of these bilateral lung changes can be an important prognostic tool. 21 Chuang et al. 31 also J o u r n a l P r e -p r o o f reported a case where FDG/PET findings in a patient with neuroendocrine small cell carcinoma suggested COVID-19. The patient had a favorable treatment response but imaging showed bilateral, multifocal, hypermetabolic ground glass opacities which were suggestive of infectious etiology. These ground-glass opacities were present in a "crazy-paving" pattern. The patient eventually presented with symptoms and was found to have a positive blood test. 31

Pulmonary pathology of COVID-19 observed in the general infected population showed congested and edematous lungs with patchy involvement and diffuse consolidation. Microscopically, airway inflammation and alveolar zones with hyaline membranes and type 2 pneumonocyte hyperplasia were observed. 32 The pathological observations of lung cancer patients with COVID-19 were largely reported through case studies and generally aligned with these observations. Tian et al. 33 

Laboratory findings are valuable prognostic tools in patients with COVID-19 infection. A meta-analysis by Zhang et al. 34 found that the most prevalent laboratory findings reported in the general COVID-19 population was increased J o u r n a l P r e -p r o o f C-reactive protein (CRP), hypoalbuminemia, increased lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR) and interleukin-6 (IL-6) levels, lymphopenia, and decreased eosinophils. In a subgroup analysis, increased CRP, lymphopenia and increased LDH were associated with worse outcomes due to severe illness.

In a cohort of lung cancer patients that underwent thoracic surgery, postoperative reduction in total protein and albumin were found to be significantly associated with fatality (p < 0.05). 8 An increase in LDH and liver enzymes also showed marginal associations with death (p = 0.05 and p = 0.055, respectively). 8 In the study by Cai et al. 25 year-old man with metastatic lung adenocarcinoma and febrile neutropenia using only broad spectrum antibiotics and respiratory support due to controversial reports of G-CSF use. A case series by Nawar et al. 40 noted that three cancer patients with COVID-19 who were administered G-CSF were observed to have a rising neutrophil to lymphocyte ratio within 24 hours. All three patients suffered respiratory decline within 72 hours of administration.

A total of 17 articles included COVID-19 related mortality outcomes in patients with lung cancer with rates ranging from 17.7% to 55%. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 25, [41] [42] [43] [44] [45] [46] Twelve of these studies included mortality rate for both lung cancer patients and other cancer types and thus were compared in the meta-analysis. [5] [6] [7] [8] [9] [10] [11] [12] [13] 41, 43, 44 Although majority of these studies reported higher rates of mortality in the lung cancer patients, this was not replicated across all studies. [6] [7] [8] [9] [10] [11] [12] [13] Pooled analysis of these trials noted a statistically significant increase in mortality rate in lung cancer patients with OR 1.62 (95% CI: 1.06 -2.48). There was no strong study-specific heterogeneity based on l 2 (9%) and tau 2 tests, p-value 0.79. Also, there was no significant funnel plot asymmetry or bias in the meta-analysis (p=0.358).

Few studies not included in the meta-analysis reported lung cancer specific mortality alone. The largest global registry of thoracic malignancies to date was reported in the ongoing TERAVOLT observational study, which reported high rates of death at 33% in patients (n=200) diagnosed with COVID-19 infection during their preliminary analysis. 14 Univariate analysis confirmed age greater than 65, current or history of smoking, presence of medical comorbidities such as hypertension and chronic obstructive pulmonary disease, and treatment with chemotherapy alone increased risk of death. Multivariate analysis in this cohort revealed that only smoking history was associated with increased risk of death. A case series of 6 lung cancer patients reported similar mortality rate of 33.3%. 25 In another cohort of 69 lung cancer patients, the rate of death was reported to be lower at 24% among 67 patients with available data, however 59% of these J o u r n a l P r e -p r o o f patients were found to be exposed to immune checkpoint inhibitors (ICI) posing the question if ICI therapy is associated with less mortality. 42 This was further highlighted in the TERAVOLT study by Garassino et al. 14 who also reported no association with increased mortality in the 23% of patients who received ICI alone on univariate analysis, OR for death 1.385 (95% CI: 0.524-3.639).

Another large study by Pinato et al. 45 which included 890 cancer patients out of which 119 were lung cancer patients, graphically represented an unadjusted mortality rate close to 40% (exact rate not given) in lung cancer patients with both active and treated disease. In a series of 138 cancer patients, 9 of which had lung cancer, Pinto et al. 46 reported an OR for death of 0.78 (95% CI: 0.16-3.74) suggesting no increase in mortality for lung cancer patients. Alvarez et al. 47 did not have lung cancer specific mortality, however, the highest rates of deaths at 53% (8/15) in cancer patients (n=36) were in lung cancer subtype.

Nine studies reported on the severity of infection in lung cancer patients with COVID-19 infection with rates of severe infection ranging from 20 to 71.4%. 8, 11, 22, 42, [48] [49] [50] [51] [52] The small sample of patients in these cohorts precluded meta-analysis of the data. Severity of illness was defined differently amongst these studies. Higher severity of infection has been reported in all but 2 of the 7 studies that compared rates to other cancer patients. 8, 11, 22, [48] [49] [50] 52 While in the study by Ma et al. 49 , the rates of severe illness were close at 50% (n=4/8) versus 54% (n=20/37) in lung cancer and other cancer patients, respectively, the results of a smaller study by Liang et al. 48 showed a larger variation with only 20% (n=1/5) severe illness noted in lung cancer patients compared to 50% in other cancer types (n=9/18).

Criteria for hospitalization, ICU admission, and mechanical ventilation vary based on institutional policy of the centers in which the studies were conducted. The TERAVOLT study defined criteria for ICU admission as needing more intensive monitoring, ventilation, and/or resuscitation. 14 The rate of ICU admissions was reported to be higher in lung cancer patients versus other cancer types at 27.3% versus 19%, respectively, as noted in a retrospective study by Dai et al. 11 Out of the 22 lung cancer patients, 4 (18.2%) required mechanical ventilation. Four other lung cancer only studies ranging from small case series to larger retrospective cohorts reported highly variable rates in ICU admissions. 14, 25, 42, 51 In the largest cohort of lung cancer patients from TERAVOLT cohort, ICU admission rate was low at 9% of hospitalized patients and only 6% required mechanical ventilation. 14 In contrast, the study by Luo et al. 42 , which included 69 lung cancer patients with majority having prior exposure to PD-1 blockade, reported significantly higher ICU admission rate of 21.7% and 18.8% required mechanical ventilation. Similarly, ICU admission rates varied greatly from 0% in a series of 17 lung cancer patients, 13 of which were hospitalized, to 33.3% (all requiring mechanical ventilation) in a series of 6 patients. 25, 51 

In the TERAVOLT cohort, type of treatment did not affect mortality on multivariate analysis however treatment with chemotherapy alone increased risk of mortality in a univariate analysis, OR 2.54 (95% CI:1.09 -6.11). Higher rates of hospitalization were also seen in patients being treated with chemotherapy alone (33%) compared to patients on ICI alone (25%) or tyrosine kinase inhibitor (TKI) alone (16) . 14 Luo et al. 42 studied the effect of immune checkpoint inhibitors (ICI) on outcomes of lung cancer patients diagnosed with COVID-19 infection. Authors concluded no significant increase in disease severity, described as a composite score of ICU admissions, intubation, transition to do not intubate (DNI) and death, in 41 (59%) patients with previous exposure to ICI. 42 In the study by Stroppa et al. 43 4 out of 8 lung cancer patients were on ICI therapy; these J o u r n a l P r e -p r o o f patients had a moderate disease course with favorable outcomes and no deaths.

In contrast, a study by Robliotti et al. 50 Following diagnosis of COVID-19 infection, another challenging decision is to halt or continue treatment. Outcomes varied significantly regardless of decision to hold or continue treatment depending on the type of lung cancer treatment patient was receiving. 18, 20, 21, 23 A study published by a group at Memorial Sloan Kettering Cancer Center showed poorer outcomes with immune checkpoint inhibitors (ICI) while chemotherapy and surgery did not confer increased risk. 50 Guerini et al. 24 also reported a case with poor outcomes following treatment with ICI and steroids. Proposed mechanisms include T-cell hyperactivation and release of cytokines from immune checkpoint inhibition resulting in exaggerated injury of lung epithelial cells. 11, 50 However, all of these studies included a small J o u r n a l P r e -p r o o f population of patients. In contrast, Garassino et al. 14 in their large registry of lung cancer patients with COVID-19 concluded increased mortality with chemotherapy in univariate analysis with no adverse effect from ICI therapy. Additional data with larger patient numbers, however, is warranted before making conclusive decisions on whether certain treatments should be stopped or continued.

Additionally, whether the length and timing of different therapies administered in these patients has an impact on mortality or adverse outcomes has yet to be determined and should be further studied.

Our study was limited by data gathered from small series and observational studies. Significant heterogeneity exists in the type of articles available for our review ranging from case reports to small observational studies. Additionally, the conclusions of our meta-analysis are limited by the unavailability of sufficient patient-level data to conduct further analysis to understand how comorbidities, disease stage, and patient characteristics play a role in the increased mortality rate in this group. Consequently, we could not definitively determine whether overlap was present in the patient data reported in the various studies we included for meta-analysis. Given the relatively new onset of the pandemic with evolving information regarding the SARS-CoV-2 virus and the scope of this review, these limitations are unavoidable.

Clinical characteristics, laboratory and radiographic findings were similar in lung cancer patients with COVID-19 compared to the general population. However, certain challenges to diagnosis do exist given the underlying abnormal lung pathology or secondary to surgical or treatment related changes. COVID-19 infection in lung cancer patients is associated with increased mortality compared to other malignancies. Severity of illness specifically respiratory complications, rates of ICU admissions and mechanical ventilation are also higher. Increased risk of adverse outcomes based on the type of treatment received is however J o u r n a l P r e -p r o o f controversial with ICI increasing risk in some studies while chemotherapy in others. Until more definitive data is available, lung cancer directed treatment should not be held in mild to moderate cases and should be restarted as soon as safely possible in severe cases of COVID-19 infection.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Dr. Kim discloses research funding (to institution) from AstraZeneca, BMS, Novartis, Regeneron, Tesaro, Karyopharm, and Debiopharm. He has served as a consultant for Novartis.

All remaining authors have declared no conflicts of interest.

Informed consent was not obtained for this study given it included secondary analysis of existing data with no reported patient identifiers or risk to subjects. 

Coronavirus disease (COVID-19): a scoping review

An interactive web-based dashboard to track COVID-19 in real time

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe

Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis

Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Improved tests for a random effects meta-regression with a single covariate

Bias in meta-analysis detected by a simple, graphical test

A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab

Alert to Potential Contagiousness: A Case of Lung Cancer With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2

Journal of thoracic oncology : official publication of the International Association for the Study of

Clinical and Radiographic Presentations of COVID-19 Among Patients Receiving Radiation Therapy for Thoracic Malignancies

Early Appearance of Coronavirus Disease 2019 Associated Pulmonary Infiltrates During Daily Radiotherapy Imaging for Lung Cancer

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

Treatment and Outcome&#xa0;of&#xa0;a Patient With&#xa0;Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2

Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab

Coronavirus Disease 2019 in the Perioperative Period of Lung Resection: A Brief Report From a Single Thoracic Surgery Department in Wuhan, People's Republic of China

Symptom severity 1 to 4 months after thoracotomy for lung cancer

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Chest-CT findings of COVID-19 in patients with pre-existing malignancies; a pictorial review

Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19

Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19

FDG PET/CT in Diagnosing COVID-19 Infection in a Cancer Patient With Exposure History But Minimal Symptoms

COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy

Pulmonary Pathology of Early-Phase

Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer

Laboratory findings of COVID-19: a systematic review and meta-analysis

Lymphopenia during the COVID-19 infection: What it shows and what can be learned

Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era

A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection? Lung cancer

Management of Febrile Neutropenia Associated With SARS-CoV-2 Infection in a Patient With Cancer

Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?

Two months of radiation oncology in the heart of Italian "red zone" during COVID-19 pandemic: paving a safe path over thin ice

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)

Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

SARS-CoV-2 Positive Hospitalized Cancer Patients during the Italian Outbreak: The Cohort Study in Reggio Emilia

COVID-19 mortality in cancer patients in a Madrid hospital during the first 3 weeks of the epidemic

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Clinical characteristics and prognosis in cancer patients with COVID-19: A single center's retrospective study

Determinants of COVID-19 disease severity in patients with cancer

Covid-19 and lung cancer: A greater fatality rate?

Chemotherapy and COVID-19 Outcomes in Patients With Cancer